Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

PURPOSE: The combination of chemotherapy and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is consistently being used as first- and second-line treatment in patients with metastatic colorectal cancer (mCRC). There is little data of the activity of bevacizumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Geva, Ravit, Vecchione, Loredana, Tejpar, Sabine, Piessevaux, Hubert, Van Cutsem, Eric, Prenen, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558253/
https://www.ncbi.nlm.nih.gov/pubmed/23378775
http://dx.doi.org/10.2147/OTT.S41383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558253/
https://www.ncbi.nlm.nih.gov/pubmed/23378775
http://dx.doi.org/10.2147/OTT.S41383

Ejemplares similares